BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

Since its 2016 launch, CARB-X has awarded $249.1 million across 67 therapeutics, vaccines and rapid diagnostic programs against the most serious drug-resistant bacteria identified by the WHO and CDC. Nine of those awards went to...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund

The International Federation of Pharmaceutical Manufacturers & Associations has spearheaded the creation of the AMR Action Fund, which has lined up about $1 billion from over 20 pharmas to invest in biotechs developing solutions to...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

CapitalBio Technology raises over $113M in pre-IPO round CapitalBio Corp. subsidiary CapitalBio Technology Co Ltd. raised over RMB800 million ($113 million) in a pre-IPO financing round last week led by Guangdong Boyi Design Institute Co....
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...NK-104) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) Be The Match BioTherapies CASI Pharmaceuticals Inc. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Jiangsu...
BioCentury | Mar 22, 2019
Company News

Germany to invest in CARB-X

...Ministry of Education and Research (BMBF) plans to contribute €39 million ($44.3 million) to the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
...will sit on CARB-X's governing board, which plans funding strategies and investment decisions. Mary Romeo, Staff Writer Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Federal...
BioCentury | Mar 1, 2019
Company News

CARB-X adds new members to increase number of funded antimicrobial research projects

...the Wellcome Trust, the California Life Sciences Institute, RTI International and the Massachusetts Biotechnology Council. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
BioCentury | Jan 4, 2019
Financial News

Microbiome company Vedanta raises $27M series C round

...compared with placebo. The program received a $5.4 million research grant in 2017 from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
BioCentury | Dec 24, 2018
Financial News

Microbiome company Vedanta raises $27M series C round

...compared with placebo. The program received a $5.4 million research grant in 2017 from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
BioCentury | Oct 26, 2018
Regulation

Learning the limits of limited use

...in the past. But according to Barry Eisenstein, SAB chair and CMO of the non-profit Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
...needle on antibiotics development. Companies and Institutions Mentioned Achaogen Inc. (NASDAQ:AKAO), South San Francisco, Calif. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
Items per page:
1 - 10 of 33
BioCentury | Feb 2, 2021
Finance

Prophylactic antibacterials backed by CARB-X: Data Byte

Since its 2016 launch, CARB-X has awarded $249.1 million across 67 therapeutics, vaccines and rapid diagnostic programs against the most serious drug-resistant bacteria identified by the WHO and CDC. Nine of those awards went to...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Bridging the valley of death: a conversation with Thomas Cueni about the AMR Fund

The International Federation of Pharmaceutical Manufacturers & Associations has spearheaded the creation of the AMR Action Fund, which has lined up about $1 billion from over 20 pharmas to invest in biotechs developing solutions to...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Pharmas to invest $1 billion in biotechs to fight AMR as bridge to market reforms

Twenty-three pharmas have banded together to create a $1 billion fund to provide bridges from Phase II to approval for biotechs trying to advance products that combat antimicrobial resistance. The AMR Action Fund will be...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

CapitalBio Technology raises over $113M in pre-IPO round CapitalBio Corp. subsidiary CapitalBio Technology Co Ltd. raised over RMB800 million ($113 million) in a pre-IPO financing round last week led by Guangdong Boyi Design Institute Co....
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

...NK-104) Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) Be The Match BioTherapies CASI Pharmaceuticals Inc. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Jiangsu...
BioCentury | Mar 22, 2019
Company News

Germany to invest in CARB-X

...Ministry of Education and Research (BMBF) plans to contribute €39 million ($44.3 million) to the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
...will sit on CARB-X's governing board, which plans funding strategies and investment decisions. Mary Romeo, Staff Writer Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Federal...
BioCentury | Mar 1, 2019
Company News

CARB-X adds new members to increase number of funded antimicrobial research projects

...the Wellcome Trust, the California Life Sciences Institute, RTI International and the Massachusetts Biotechnology Council. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
BioCentury | Jan 4, 2019
Financial News

Microbiome company Vedanta raises $27M series C round

...compared with placebo. The program received a $5.4 million research grant in 2017 from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
BioCentury | Dec 24, 2018
Financial News

Microbiome company Vedanta raises $27M series C round

...compared with placebo. The program received a $5.4 million research grant in 2017 from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
BioCentury | Oct 26, 2018
Regulation

Learning the limits of limited use

...in the past. But according to Barry Eisenstein, SAB chair and CMO of the non-profit Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
...needle on antibiotics development. Companies and Institutions Mentioned Achaogen Inc. (NASDAQ:AKAO), South San Francisco, Calif. Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator...
Items per page:
1 - 10 of 33